| Original language | English |
|---|---|
| Pages (from-to) | 6079-6086 |
| Number of pages | 8 |
| Journal | Clinical Cancer Research |
| Volume | 15 |
| Issue number | 19 |
| DOIs | |
| Publication status | Published - 1 Oct 2009 |
| Externally published | Yes |
Funding
Grants Sp 581/4-1, Sp 581/4-2 (DFG Forschergruppe FCR411 'Radionuklidtherapie') as well as SFB 824 (DFG Sonderforschungsbereich 824) from the Deutsche Forschungsgemeinschaft, Bonn, Germany, and by a grant from the Wilhelm-Sander-Stiftung (2008.037.1) to C. Spitzweg, as well as the DFG-funded Nanosystems initiative Munich and EG-funded Project GIANT to M. Cgris and E. Wagner.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Austrian Fields of Science 2012
- 301207 Pharmaceutical chemistry
Keywords
- MEDULLARY-THYROID CANCER
- PROSTATE-CANCER
- SODIUM/IODIDE SYMPORTER
- IN-VIVO
- DNA COMPLEXES
- EXPRESSION
- CELLS
- NIS
- OLIGOETHYLENIMINE
- RADIOVIROTHERAPY
Fingerprint
Dive into the research topics of 'Targeted Radioiodine Therapy of Neuroblastoma Tumors following Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver